Jupiter Investment Management Portfolio holdings
Top Buys
| 1 |
Abbott
ABT
|
+$119M |
| 2 |
PARA
Paramount Global Class B
PARA
|
+$102M |
| 3 |
Valero Energy
VLO
|
+$97.2M |
| 4 |
Baxter International
BAX
|
+$94.2M |
| 5 |
HCA Healthcare
HCA
|
+$89M |
Top Sells
| 1 |
MON
Monsanto Co
MON
|
+$91.7M |
| 2 |
MDVN
MEDIVATION, INC.
MDVN
|
+$74.6M |
| 3 |
Amgen
AMGN
|
+$72.5M |
| 4 |
Prudential Financial
PRU
|
+$46.2M |
| 5 |
Intel
INTC
|
+$45.8M |
Sector Composition
| 1 | Healthcare | 23.11% |
| 2 | Technology | 16.98% |
| 3 | Consumer Discretionary | 9.74% |
| 4 | Financials | 8.95% |
| 5 | Consumer Staples | 8.26% |
Similar funds
Jupiter Investment Management's Q2 2016 Portfolio in Review
As of Q2 2016, Jupiter Investment Management held 579 positions worth $5.34B, up 9.2% from $4.89B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Jupiter Investment Management deployed $475M of net new capital in Q2 2016, opening 117 new positions and adding to 160 existing holdings. Its largest new stake was Applied Materials: 3,120,777 shares worth $74.8M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Monsanto Co, an estimated $91.7M trimmed.
- Jupiter Investment Management's largest Q2 2016 buy was Applied Materials: 3,120,777 shares worth $74.8M.
- Jupiter Investment Management added most to Abbott in Q2 2016, an estimated $119M increase.
- Jupiter Investment Management's biggest Q2 2016 reduction was Monsanto Co, cutting an estimated $91.7M.
- Jupiter Investment Management fully exited MEDIVATION, INC. in Q2 2016, selling an estimated $74.6M.
- Jupiter Investment Management's ten largest holdings make up 20% of its $5.34B portfolio in Q2 2016.
- Jupiter Investment Management opened 117 new positions and closed 155 in Q2 2016.
- Jupiter Investment Management's portfolio value rose 9.2% quarter-over-quarter to $5.34B.
Based on Jupiter Investment Management's 13F filing for Q2 2016, filed 22 Jul 2016.